Our Yoram Unguru writes, “Having cancer is hard enough without unnecessary and preventable impediments such as drug shortages, which represent a particularly vexing challenge. In the United States, shortages of drugs for cancer and other diseases over the past decade have become the new normal and the problem is getting worse.”

Quick Read

Tens of millions of dollars have been spent in a legal fight between two US scientific powerhouses, but a recent ruling by the US Patent Office could signal its end

Quick Read

New York City Council Speaker Corey Johnson, who is HIV-positive, has endorsed a plan to make Truvada, or PrEP, generic

Quick Read

Bob Field was set to kick off his second course of BCG — a potent immunotherapy that treats his fast-growing bladder cancer. Instead, the New York City banking executive got a call from his urologist’s office, canceling that week’s appointment

Quick Read

The CRISPR patent dispute between the University of California, Berkeley, and the Broad Institute is finally over

Quick Read

A federal judge in Texas invalidated four key patents for the dry-eye treatment Restasis on Monday, dealing a blow to its manufacturer, Allergan, which had sought to protect its patents by transferring them to a Native American tribe

Quick Read

How to Protect a Drug Patent?

September 11, 2017

Sell it to a Native American Tribe. The drugmaker Allergan announced Friday that it had transferred its patents on a best-selling eye drug to the Saint Regis Mohawk Tribe in upstate New York — an unusual gambit to protect the drug from a patent dispute

Quick Read

Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales

Quick Read